Top ▲

Pruritus

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1231
Name:Pruritus
Associated with:0 target
4 immuno-relevant ligands
Description
Itching which can be associated with a number of disorders, commonly a symptom of seasonal allergies, hay fever, and eczema.

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Pruritus

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
itacitinib
Immuno Disease Comments: Phase 2 clinical candidate for chronic pruritus (see NCT02909569).
Clinical Use: INCB039110 is being assessed in Phase 2 clinical trials as a potential treatment for indications such as rheumatoid arthritis (RA), post essential thrombocythemia myelofibrosis, chronic plaque psoriasis and non-small cell lung cancer (NSCLC). Phase 3 trials in chronic graft-versus-host disease are also underway. Click here to link to ClinicalTrials.gov's complete list of INCB039110 studies. | View clinical data
hydroxyzine
Immuno Disease Comments: A sedating antihistamine that can be used to aid sleep in patients suffering from pruritus.
Clinical Use: The sedative action of hydroxyzine is used to treat anxiety and tension and is combined with other medications in anesthesia. Hydroxyzine may also be used to control nausea and vomiting and be used as an antihistamine to control pruritic symptoms. | View clinical data
alimemazine
Immuno Disease Comments: Approved drug for allergic pruritus.
Clinical Use: Used to treat allergic pruritis and motion sickness. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed human molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. Quantitative data at bovine targets is published in [2] which reports anti-histaminergic and anti-muscarinic effects of alimemazine in bovine brain. Alimemazine antagonises binding to bovine brain preparations (i.e. muscarinic acetylcholine receptor binding) with a Ki of 38nM [2]. | View biological activity
fludroxycortide
Immuno Disease Comments: Approved for relief of pruritic symptoms of corticosteroid-responsive skin conditions.
Clinical Use: Fludroxicortide is a topical corticosteroid drug. It is used to relieve inflammatory and pruritic symptoms of corticosteroid-responsive skin conditions. | View clinical data
Bioactivity Comments: The only available affinity data for this drug at the glucocorticoid receptor is contained in the DRUGMATRIX in vitro pharmacology data [1], which reports a Ki of 2.02nM. We do not map a primary drug target in this case. | View biological activity

References

Show »

1. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

2. Kubo N, Shirakawa O, Kuno T, Tanaka C. (1987) Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol, 43 (3): 277-82. [PMID:2884340]